Antioxidants in antidiabetic drugs may fuel tumor spread: study

Some compounds in antidiabetic drugs known as antioxidants may fuel the spread of tumor, a study led by Chinese researchers said Wednesday.

The study, published in the U.S. journal Science Translational Medicine, suggested that antioxidants may need to be administered with caution in diabetic patients with cancer.

Diabetes is suspected to raise the risk of many cancers, and the number of diabetic patients who also have cancer is growing, but how antidiabetic drugs affect cancer is poorly understood, said the study led by Hongting Zheng and Shicang Yu of the Third Military Medical University in Chongqing, China.

Antioxidants, compounds that protect cells from toxic reactive oxygen species, are commonly used to treat patients with diabetes, but mounting evidence from animal studies highlights the potential of these drugs to accelerate either cancer growth or metastasis.

In the new study, the researchers studied the effects of two common classes of antidiabetic medications with antioxidant properties in mice with colon and liver cancers.

The researchers found that while these drugs did not raise the risk of developing cancers, they sped the spread of existing tumors.

Further research revealed that the drugs activated the so-called NRF2 signaling pathway, which accelerated tumor metastasis.

If proven in humans, the findings would caution against giving this type of antioxidant-containing medication to diabetic cancer patients.

"Our results challenge traditional views on the use of antioxidants, which thought that these drugs protect cells from damage caused by free oxygen radicals, reducing the risk of tumorigenesis and improving the prognosis of cancer patients," Zheng and Yu said in an email to Xinhua.

"However, our study found that antioxidants may have a negative effect in certain circumstances, suggesting that we cannot abuse antioxidants." Endit